Taro Pharmaceutical Industries Company Profile (NYSE:TARO)

About Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries logoTaro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:TARO
  • CUSIP: N/A
  • Web: www.taro.com
Capitalization:
  • Market Cap: $4.29114 billion
  • Outstanding Shares: 40,489,000
Average Prices:
  • 50 Day Moving Avg: $105.17
  • 200 Day Moving Avg: $111.63
  • 52 Week Range: $92.28 - $124.52
P/E:
  • Trailing P/E Ratio: 10.79
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $806.92 million
  • Price / Sales: 5.33
  • Book Value: $52.84 per share
  • Price / Book: 2.01
Profitability:
  • EBIDTA: $465.05 million
  • Net Margins: 49.69%
  • Return on Equity: 19.71%
  • Return on Assets: 17.74%
Debt:
  • Current Ratio: 9.40%
  • Quick Ratio: 8.70%
Misc:
  • Average Volume: 102,992 shs.
  • Beta: 0.65
  • Short Ratio: 22.83
 

Frequently Asked Questions for Taro Pharmaceutical Industries (NYSE:TARO)

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its earnings results on Monday, May, 22nd. The company reported $2.05 earnings per share for the quarter. The company earned $196.41 million during the quarter. Taro Pharmaceutical Industries had a net margin of 49.69% and a return on equity of 19.71%. View Taro Pharmaceutical Industries' Earnings History.

When will Taro Pharmaceutical Industries make its next earnings announcement?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Taro Pharmaceutical Industries.

Who are some of Taro Pharmaceutical Industries' key competitors?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:

  • Dilip Shantilal Shanghvi, Chairman of the Board
  • Uday Baldota, Chief Executive Officer, Director
  • Abhay Gandhi, Vice Chairman of the Board
  • Mariano Balaguer, Chief Financial Officer, Chief Accounting Officer, Vice President
  • Stephen Manzano Esq., Group Vice President, General Counsel, Secretary, Corporate Compliance
  • Itamar Karsenti, Vice President - Head of Operations, Haifa
  • Chantal LeBlanc, Vice President - Global Quality
  • Daryl LeSueur, Vice President - Head of Operations, Brampton, Canada
  • Michael Perfetto, Group Vice President and Chief Commercial Officer of the Generic Rx and OTC Business
  • Michael Teiler, Group Vice President - Portfolio Management

Who owns Taro Pharmaceutical Industries stock?

Taro Pharmaceutical Industries' stock is owned by a number of of institutional and retail investors. Top institutional investors include Matthews International Capital Management LLC (1.99%), Schroder Investment Management Group (1.68%), FMR LLC (1.15%), Renaissance Technologies LLC (0.67%), APG Asset Management N.V. (0.55%) and State Street Corp (0.51%). View Institutional Ownership Trends for Taro Pharmaceutical Industries.

Who sold Taro Pharmaceutical Industries stock? Who is selling Taro Pharmaceutical Industries stock?

Taro Pharmaceutical Industries' stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Schroder Investment Management Group, Renaissance Technologies LLC, Virginia Retirement Systems ET AL, Carmignac Gestion, Northern Trust Corp, Andra AP fonden and Korea Investment CORP. View Insider Buying and Selling for Taro Pharmaceutical Industries.

Who bought Taro Pharmaceutical Industries stock? Who is buying Taro Pharmaceutical Industries stock?

Taro Pharmaceutical Industries' stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Dimensional Fund Advisors LP, River Road Asset Management LLC, Aperio Group LLC, AHL Partners LLP, Acadian Asset Management LLC, Citadel Advisors LLC and Clinton Group Inc.. View Insider Buying and Selling for Taro Pharmaceutical Industries.

How do I buy Taro Pharmaceutical Industries stock?

Shares of Taro Pharmaceutical Industries can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of Taro Pharmaceutical Industries stock can currently be purchased for approximately $106.16.


MarketBeat Community Rating for Taro Pharmaceutical Industries (NYSE TARO)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Taro Pharmaceutical Industries (NYSE:TARO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Taro Pharmaceutical Industries (NYSE:TARO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017Credit Suisse GroupDowngradeOutperform -> NeutralLowView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Taro Pharmaceutical Industries (NYSE:TARO)
Earnings by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)
Earnings History by Quarter for Taro Pharmaceutical Industries (NYSE TARO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017N/AView Earnings Details
5/22/2017Q4$2.05$196.41 millionViewN/AView Earnings Details
8/10/2016Q1$2.59$215.30 million$233.80 millionViewN/AView Earnings Details
5/26/2016Q4$2.68$265.07 millionViewListenView Earnings Details
2/10/2016Q316$4.41$974.38 million$258.30 millionViewN/AView Earnings Details
8/6/2015Q116$2.42$1.01 billion$215.30 millionViewN/AView Earnings Details
5/26/2015Q415$3.56$881.79 million$244.18 millionViewListenView Earnings Details
2/10/2015Q315$3.33$213.60 million$237.70 millionViewN/AView Earnings Details
5/27/2014Q4$5.93$2.10$165.13 million$187.20 millionViewN/AView Earnings Details
2/10/2014Q214$2.59$185.70 million$213.60 millionViewN/AView Earnings Details
11/12/2013Q3$2.15ViewN/AView Earnings Details
8/7/2013Q114$1.32$159.15 million$153.20 millionViewN/AView Earnings Details
5/23/2013Q4 2013$1.10$145.00 million$165.10 millionViewN/AView Earnings Details
11/1/2012Q213$1.46$138.25 million$160.97 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Taro Pharmaceutical Industries (NYSE:TARO)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Taro Pharmaceutical Industries (NYSE:TARO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Taro Pharmaceutical Industries (NYSE:TARO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Taro Pharmaceutical Industries (NYSE:TARO)
Latest Headlines for Taro Pharmaceutical Industries (NYSE:TARO)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Taro Pharmaceutical Industries Ltd. : September 14, 2017
finance.yahoo.com - September 15 at 9:37 AM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 10:58 AM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (TARO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - September 9 at 4:16 PM
finance.yahoo.com logoTaro Announces Joining of CEO
finance.yahoo.com - September 2 at 9:18 AM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : August 21, 2017
finance.yahoo.com - August 23 at 12:19 PM
americanbankingnews.com logoZacks: Taro Pharmaceutical Industries Ltd. (TARO) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - August 18 at 8:36 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Taro Pharmaceutical Industries Ltd.
finance.yahoo.com - August 13 at 6:41 AM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (NYSE:TARO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 11 at 8:42 PM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (TARO) Downgraded by TheStreet to C+
www.americanbankingnews.com - August 11 at 3:24 PM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : August 9, 2017
finance.yahoo.com - August 10 at 8:33 AM
finance.yahoo.com logoIHS Markit Score upgrades Taro Pharmaceutical Industries Ltd to 71 out of 100, despite ranking positively in only one IHS Markit category.
finance.yahoo.com - August 10 at 8:33 AM
finance.yahoo.com logoTaro Provides Results for Quarter Ended June 2017
finance.yahoo.com - August 9 at 8:02 AM
finance.yahoo.com logoTaro posts 1Q profit
finance.yahoo.com - August 9 at 8:02 AM
seekingalpha.com logoTaro Pharmaceutical: Solid Cash-Rich Business With No Debt And A Catalyst
seekingalpha.com - August 5 at 7:34 AM
finance.yahoo.com logoTaro to Announce First Quarter Results on August 8, 2017
finance.yahoo.com - August 3 at 7:47 AM
americanbankingnews.com logo Taro Pharmaceutical Industries Ltd. (TARO) Given Average Rating of "" by Brokerages
www.americanbankingnews.com - August 2 at 10:30 AM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (TARO) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:31 AM
americanbankingnews.com logo Taro Pharmaceutical Industries Ltd. (TARO) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - July 30 at 10:42 AM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (TARO) Lifted to B- at TheStreet
www.americanbankingnews.com - July 23 at 9:26 PM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (NYSE:TARO) Downgraded by BidaskClub
www.americanbankingnews.com - July 16 at 9:32 PM
americanbankingnews.com logoContrasting Amphastar Pharmaceuticals (AMPH) & Taro Pharmaceutical Industries (TARO)
www.americanbankingnews.com - July 15 at 10:04 PM
finance.yahoo.com logo[$$] In Hot Pursuit of Indian Growth Stocks
finance.yahoo.com - July 14 at 8:56 AM
finance.yahoo.com logoETFs with exposure to Taro Pharmaceutical Industries Ltd. : July 12, 2017
finance.yahoo.com - July 13 at 10:14 AM
finance.yahoo.com logoETFs with exposure to Taro Pharmaceutical Industries Ltd. : June 27, 2017
finance.yahoo.com - June 27 at 8:13 PM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q4, 2017 By the Numbers : June 26, 2017
finance.yahoo.com - June 27 at 8:53 AM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (TARO) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - June 24 at 3:38 PM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bullish Manner : TARO-US : June 21, 2017
finance.yahoo.com - June 22 at 2:00 PM
finance.yahoo.com logoTaro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2017
finance.yahoo.com - June 22 at 2:00 PM
americanbankingnews.com logoTheStreet Lowers Taro Pharmaceutical Industries Ltd. (TARO) to C
www.americanbankingnews.com - June 18 at 11:28 PM
americanbankingnews.com logoBidAskClub Lowers Taro Pharmaceutical Industries Ltd. (TARO) to Sell
www.americanbankingnews.com - June 10 at 12:02 AM
bloomberg.com logoSun Pharma Warns 'New Normal' Will Push Down Its Sales Next Year
www.bloomberg.com - May 27 at 6:09 AM
nasdaq.com logoOversold Conditions For Taro Pharmaceutical Industries (TARO)
www.nasdaq.com - May 25 at 4:05 AM
finance.yahoo.com logoEdited Transcript of TARO earnings conference call or presentation 23-May-17 12:00pm GMT
finance.yahoo.com - May 25 at 4:05 AM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (TARO) Stock Rating Lowered by Credit Suisse Group AG
www.americanbankingnews.com - May 23 at 11:16 AM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (TARO) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 23 at 9:27 AM
finance.yahoo.com logoTaro Provides Results for Year Ended March 31, 2017
finance.yahoo.com - May 22 at 7:07 PM
finance.yahoo.com logoTaro posts 4Q profit
finance.yahoo.com - May 22 at 7:07 PM
streetinsider.com logoCrescita Therapeutics™ Announces 2017 First Quarter Results
www.streetinsider.com - May 16 at 8:49 AM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : May 15, 2017
finance.yahoo.com - May 15 at 7:22 PM
finance.yahoo.com logoTaro to Announce Results for Year Ended March 31, 2017 on May 22, 2017
finance.yahoo.com - May 15 at 7:22 PM
americanbankingnews.com logoTaro Pharmaceutical Industries (TARO) Receiving Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 5 at 10:56 PM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : May 4, 2017
finance.yahoo.com - May 4 at 10:31 AM
americanbankingnews.com logoTaro Pharmaceutical Industries (TARO) Earning Very Positive Media Coverage, Report Finds
www.americanbankingnews.com - May 2 at 2:56 PM
americanbankingnews.com logoTaro Pharmaceutical Industries (TARO) Receives News Sentiment Score of 0.10
www.americanbankingnews.com - April 26 at 12:34 PM
streetinsider.com logoCrescita Therapeutics Enters Agreement with Taro Pharmaceuticals (TARO) for Pliaglis
www.streetinsider.com - April 26 at 8:54 AM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : April 25, 2017
finance.yahoo.com - April 25 at 7:07 PM
finance.yahoo.com logoTaro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : April 24, 2017
finance.yahoo.com - April 24 at 10:46 AM
americanbankingnews.com logoTaro Pharmaceutical Industries (TARO) Earning Somewhat Critical News Coverage, Study Finds
www.americanbankingnews.com - April 22 at 8:31 AM
americanbankingnews.com logoTaro Pharmaceutical Industries (TARO) Receives Daily Media Sentiment Score of 0.50
www.americanbankingnews.com - April 18 at 11:30 AM
americanbankingnews.com logoTaro Pharmaceutical Industries Ltd. (TARO) Raised to B at TheStreet
www.americanbankingnews.com - April 17 at 12:52 AM

Social

Chart

Taro Pharmaceutical Industries (TARO) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff